| Patents for A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020) |
|---|
| 09/27/2005 | CA2428206C Methods for the treatment of cellular proliferative disorders |
| 09/27/2005 | CA2149120C Monoclonal antibody which specifically binds to tumor vascular endothelium and uses thereof |
| 09/22/2005 | WO2005087925A1 Recombinant gene, disease animal model and method of evaluating test substance |
| 09/22/2005 | WO2005087789A1 Protein c and endothelial protein c receptor polymorphisms as indicators of subject outcome |
| 09/22/2005 | WO2005087288A1 Medicinal preparation for angiogenesis |
| 09/22/2005 | WO2005087287A1 Novel tissue engineered scaffolds derived from copper capillary alginate gels |
| 09/22/2005 | WO2005087271A1 Compositions comprising cells and magnetic materials for targeted delivery |
| 09/22/2005 | WO2005087270A1 Anti-vaginitis compositions comprising a triazole |
| 09/22/2005 | WO2005087269A1 Method of inhibiting tumor proliferation |
| 09/22/2005 | WO2005087268A1 Axon regeneration promoter |
| 09/22/2005 | WO2005087267A1 Remedies for prostatic hypertrophy |
| 09/22/2005 | WO2005087262A1 Chicken anemia virus vaccine from cell line |
| 09/22/2005 | WO2005087249A1 Protease inhibitor and preventives or remedies for diseases |
| 09/22/2005 | WO2005087242A1 Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method |
| 09/22/2005 | WO2005087219A1 Memory fixation accelerator |
| 09/22/2005 | WO2005087212A1 Combined pharmaceutical composition for the inhibition of the decline of cognitive functions |
| 09/22/2005 | WO2005087206A2 Cancer therapy comprising a nuclear receptor ligand and a hdac inhibitor |
| 09/22/2005 | WO2005086971A2 Anti-metastatic ability of mibefradil and gadolinium |
| 09/22/2005 | WO2005086834A2 Methods and compositions for reactivating acetylcholinesterase |
| 09/22/2005 | WO2005086781A2 Regulatory t cells and their use in immunotherapy and suppression of autoimmune responses |
| 09/22/2005 | WO2005074947A3 Anti-viral pharmaceutical compositions |
| 09/22/2005 | WO2005063234A3 Use of at least one effector of glutathione metabolism, together with alpha-liponic acid for the treatment of lung diseases |
| 09/22/2005 | WO2005060708A3 Canine probiotic lactobacilli |
| 09/22/2005 | WO2005053719A3 Compositions for the treatment of diseases of the oral cavity and upper respiratory tract |
| 09/22/2005 | WO2005046675A3 Methods for enhancing glutathione peroxidase activity |
| 09/22/2005 | WO2005046594A3 Methods of using and compositions comprising a jnk inhibitor for the treatment and management of asbestos-related diseases and disorders |
| 09/22/2005 | WO2005046567A3 Synergistic formulation of antioxidants and antimycobacterial agents: a method of making the same |
| 09/22/2005 | WO2005041984B1 Compositions and treatments for envelope virus infections |
| 09/22/2005 | WO2005039639B1 Pharmaceutical composition comprising a selective i1 imidazoline receptor agonist and an angiotensin ii receptor blocker |
| 09/22/2005 | WO2004112566A3 Diagnosis and treatment of nephropathy |
| 09/22/2005 | WO2004064833A8 Clindamycin phosphate foam |
| 09/22/2005 | WO2003065997A3 Anti-infarction molecules |
| 09/22/2005 | US20050210538 Screening for a developmental promoter or a developmental suppressor of oligodendrocytes, or a promoter or a suppressor of myelinogenesis, diagnostic for neuropsychiatric disorders |
| 09/22/2005 | US20050209338 Phenethanolamine derivatives for treatment of respiratory diseases |
| 09/22/2005 | US20050209329 Potentiation of therapeutic effects of fatty acids |
| 09/22/2005 | US20050209321 Such as cyclohexane-trans-1,2-diaminetetraacetic-acid-monoplatinum |
| 09/22/2005 | US20050209317 Method and compositions for treatment of chronic neuropathic pain |
| 09/22/2005 | US20050209310 Methods for modulating tumor growth and metastasis |
| 09/22/2005 | US20050209292 Cancer therapy |
| 09/22/2005 | US20050209288 Compositions comprising (S)-amlodipine malate and an angiotensin receptor blocker and methods of their use |
| 09/22/2005 | US20050209286 RXR activating molecules |
| 09/22/2005 | US20050209270 Use of 5HT3 agonists for relaxing the fundus |
| 09/22/2005 | US20050209250 olanzapine, clozapine, aripiprazole, quetiapine, amisulpride, risperidone, sertindole, asenapine, ziprasidone antipsychotic drugs, 4-(1-ethyl-propoxy)-3,6-dimethyl-2-(2,4,6-trimethylphenoxy)-pyridine, (3,6-dimethyl-2-(2,4,6-trimethyl-phenoxy)-pyridin-4-yl)-(1-ethyl-propyl)-amine as CRF antagonist |
| 09/22/2005 | US20050209244 N{5-[4-(4-methyl-piperazino-methyl)-benzoylamido]-2-methylphenyl}-4-(3-pyridyl)-2-pyrimidine-amine coated stents |
| 09/22/2005 | US20050209235 Tyrosine kinase inhibitors; antiproliferative agent; 2-(4-{4-[1-(3-Fluoro-benzyl)-1H-indazol-5-ylamino]-pyrrolo[2,1-f][1,2,4]triazin-5-ylmethyl}-[1,4]diazepan-1-yl)-ethanol combined with anticarncer agent selected from tamoxifen, toremifen, raloxifene, droloxifene, iodoxyfene, megestrol acetate and other |
| 09/22/2005 | US20050209201 allowing an ATP receptor antagonist ( Reactive Blue 2 ) to work on ATP receptors of cells to block them and thereby inhibit the release of inflammatory cytokines, particularly interleukin-6 (IL-6) and/or interleukin-8 (IL-8) |
| 09/22/2005 | US20050209198 Pharmaceutical composition comprising a bisphosphonate and a cox-2 inhibitor for the treatment of bone diseases |
| 09/22/2005 | US20050209196 Dioxolane thymine and combinations for use against 3tc/azt resistant strains of hiv |
| 09/22/2005 | US20050209185 Synergistic mixture; administering by inhalation; tiotropium bromide; metered dose inhaler, a dry powder inhaler; asthma, chronic obstructive pulmonary disease |
| 09/22/2005 | US20050209177 Combined use of genes that block oncogenic cell signalling pathways and chemotherapeutic and or radiotherapeutic agents |
| 09/22/2005 | US20050209171 Treatment of periodontal disease |
| 09/22/2005 | US20050209165 Hypercholesterolemia, cholesterol-associated benign and malignant tumors; hyperlipidemia, arteriosclerosis, and sitosterolemia; 6) (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl]-4-(2',3',4'-trimethoxybiphenyl-4-yl)azetidin-2-one |
| 09/22/2005 | US20050209141 Mast cell-derived renin |
| 09/22/2005 | US20050209140 Methods of controlling axonal growth |
| 09/22/2005 | US20050209130 Compositions and methods for treatment of rosacea |
| 09/22/2005 | US20050209128 Statins, especially (E)-7-[4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl](3R,5S)-3,5-dihydroxyhept-6-enoic acid, as nerve conduction velocity or nerve blood flow enhancers in combination with an aldose reductase inhibitor, an ACE inhibitor or an Angiotensin II antagonist |
| 09/22/2005 | US20050208678 Using capillary electrophoresis and laser induced fluorescent detection to monitor protein complex formation between membrane glycoproteins and helical polypeptides |
| 09/22/2005 | US20050208619 29 human secreted proteins |
| 09/22/2005 | US20050208612 Transglutaminase has intrinsic kinase activity |
| 09/22/2005 | US20050208580 Novel protein and method for producing the protein |
| 09/22/2005 | US20050208496 Using enhanced interleukin gene expression as diagnostic indicator of respiratory system disorders |
| 09/22/2005 | US20050208484 Isolated nucleic acid molecules encoding human drugmetobolizing proteins |
| 09/22/2005 | US20050208463 Method of screening drug |
| 09/22/2005 | US20050208161 touchi plant extract and phaseolamin mixture for limiting the absorption of carbohydrates contained in a foodstuff, for promoting weight loss in an individual; nutraceuticals |
| 09/22/2005 | US20050208152 Pharmaceutical compositions primarily for the treatment and prevention of genitourinary infections and their extragenital complications |
| 09/22/2005 | US20050208151 Treatment of rheumatoid arthritis with FLIP antagonists |
| 09/22/2005 | US20050208150 Compositions for elastrogenesis and connective tissue treatment |
| 09/22/2005 | US20050208148 Method of reducing risk of infection of a bovine teat after cessation of milking |
| 09/22/2005 | US20050208137 comprising angiogenesis inhibitor retinoic acid, taxol and polymeric carrier polylactone; treating cancer, angiogenic-dependent diseases, embolizing blood vessels, and eliminating biliary, urethral, esophageal, tracheal/bronchial obstructions, corneal neovascularization; coated stents with the mixture |
| 09/22/2005 | US20050208131 Mixing active ingredients and at least one excipient to obtain powdered mixture, compacting, breaking and sieving product to chosen mesh size to obtain similar sized granules, forming granules into unitary dosage forms; alleviates active ingredient losses during manufacture; ensures content uniformity |
| 09/22/2005 | US20050208103 Contacting sclera with a therapeutic or diagnostic agent so as to permit its passage into the choroidal and retinal tissues; no significant systemic absorption or tissue damage; eye disorders |
| 09/22/2005 | US20050208079 Glucan-based vaccines |
| 09/22/2005 | US20050208070 From Ganoderma lucidum, Salvia miltiorrhiza, and Scutellaria barbata |
| 09/22/2005 | US20050208046 TWEAK receptor |
| 09/22/2005 | US20050208044 Methods for the identification of compounds useful for the suppression of chronic neuropathic pain and compositions thereof |
| 09/22/2005 | US20050208042 Inducing lack of responsiveness to an antigen in an individual having a transplanted organ, tissue, cell; administering an effective amount of a humanized antibody; one antigen binding region of nonhuman origin and a portion of an immunoglobulin heavy chain of human origin |
| 09/22/2005 | US20050208034 Pau D' Arco, La Pacho, tabebuia heptaphylla, lactobacillus acidophilus, bifidobacterium bifidum, bifidobacterium longum, streptococcus thermophilus, lactobacillus bulgaricus, lactobacillus bulgaricus, lactobacillus paracasei, allium sativum or concentrated Garlic bulb; ingested orally |
| 09/22/2005 | US20050208033 Induction of cell apoptosis of colon cancer; anticancer agent is 5 fluoro-uracil; bacterial strain is in a live or irradiated form |
| 09/22/2005 | US20050208028 Nutrient Medium for maintaining neural cells in injured nervous system |
| 09/22/2005 | US20050207991 Aerosols for administering drugs by breathing and filling canisters with compounds like fluticasone propionate |
| 09/22/2005 | US20050207975 administering monoclonal Tac-antibodies; anticarcinogenic agents; immunotherapy |
| 09/22/2005 | CA2787978A1 Interferon-beta for anti-virus therapy for respiratory diseases |
| 09/22/2005 | CA2560046A1 Methods for suppressing tumor proliferation |
| 09/22/2005 | CA2559826A1 Traditional chinese medicine preparation for cardio-cerebral blood vessel diseases and its preparing method |
| 09/22/2005 | CA2559555A1 Protein c and endothelial protein c receptor polymorphisms as indicators of subject outcome |
| 09/22/2005 | CA2559493A1 Combined pharmaceutical composition for the inhibition of the decline of cognitive functions |
| 09/22/2005 | CA2559069A1 Axon regeneration promoter |
| 09/22/2005 | CA2558777A1 Regulatory t cells and their use in immunotherapy and suppression of autoimmune responses |
| 09/22/2005 | CA2558736A1 Chicken anemia virus vaccine from cell line |
| 09/21/2005 | EP1577673A1 The use of BNP-type and ANP-type peptides for assessing the risk of suffering from a cardiovascular complication as a consequence of volume overload |
| 09/21/2005 | EP1577391A1 Neutrokine alpha |
| 09/21/2005 | EP1577317A1 Nitrogen-containing heterocycic derivatives, medicinal compositions containing the same and medicinal use thereof |
| 09/21/2005 | EP1576963A2 Method for treating pain by peripheral administration of a neurotoxin |
| 09/21/2005 | EP1576956A2 Chromium/biotin treatment of type II diabetes |
| 09/21/2005 | EP1576370A2 Methods of diagnosing and treating diabetes and insulin resistance |
| 09/21/2005 | EP1576150A2 Methods and compositions for increasing the efficacy of biologically-active ingredients |
| 09/21/2005 | EP1576138A2 2-branched nucleosides and flaviviridae mutation |
| 09/21/2005 | EP1576110A2 Cell migration inhibiting compositions and methods and compositions for treating cancer |
| 09/21/2005 | EP1576086A2 Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| 09/21/2005 | EP1576010A2 Compositions and methods of therapy for cancers characterized by expression of the tumor-associated antigen mn/ca ix |